Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

NCT04463004 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

2

Enrollment

OTHER

Sponsor class

Conditions

COVID-19
Sars-CoV2
Pneumonia

Interventions

DRUG: Mavrilimumab
DRUG: Placebos

Sponsor

Virginia Commonwealth University

Collaborators

[object Object]